Median Female Sexual Function Index Score Research Articles

MP21-06 IMPACT OF SEXUAL DYSFUNCTION ON QUALITY OF LIFE IN WOMEN AFTER PELVIC FRACTURE

You have accessJournal of UrologyCME1 May 2022MP21-06 IMPACT OF SEXUAL DYSFUNCTION ON QUALITY OF LIFE IN WOMEN AFTER PELVIC FRACTURE Helen Gambrah, and Niels Vass Johnsen Helen GambrahHelen Gambrah More articles by this author , and Niels Vass JohnsenNiels Vass Johnsen More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002554.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Pelvic neurovascular damage accounts for the well-known association between pelvic fracture and sexual dysfunction. The impact of sexual dysfunction on quality of life has been well-documented but has historically focused on patients with lower urinary tract injuries. These injuries have been shown to be associated with higher rates of SD and therefore are more likely to influence patient-reported quality of life. We hypothesized that the presence of SD following pelvic fracture negatively impacts health-related quality of life (HrQOL) even for patients with no lower urinary tract injuries. METHODS: Women treated for pelvic fracture at a level 1 trauma center between 2012 and 2017 were invited to complete an online survey. Patients with spinal cord injuries, associated lower urinary tract injuries, and isolated acetabular fractures were excluded. Sexual function was assessed using the Female Sexual Function Index (FSFI). HrQOL was evaluated using the visual analog scale (VAS) component of the EuroQol 5 Dimensions Questionnaire (EQ-5D). Inverse probability weighting was utilized to adjust for subject nonresponse. Multivariate regression was performed to evaluate the impact of sexual function on HrQOL. RESULTS: 98 of the 780 potential subjects completed the survey (12.6%). Responders had a mean age at time of injury of 42.2 years (SD 22.4) and median time since injury of 45 months (IQR 30.0, 57.4). After weighting, median FSFI score was 19.1 (IQR 5.5, 27.7), and median EQ-5D VAS score was 71 (IQR 60, 85). Bivariate linear analysis showed that FSFI scores and time since injury were significantly associated with patient-reported HrQOL. A decrease in FSFI scores correlated to a decline in EQ-5D VAS score (β = 0.62, 95% CI 0.30–0.95, p <0.001). Additionally, after adjustment for potential confounders, FSFI, time from injury, and age were all independently associated with HrQOL, with FSFI having the largest effect size (Table 1). CONCLUSIONS: Younger age, increased time since injury, and higher FSFI scores were all independently associated with improved HrQOL scores among women with a history of traumatic pelvic fracture, with FSFI scores as the strongest independent predictor for decreased HrQOL in this patient population. These data highlight the importance of addressing sexual health issues in female pelvic trauma survivors in the post-injury setting. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e329 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Helen Gambrah More articles by this author Niels Vass Johnsen More articles by this author Expand All Advertisement PDF DownloadLoading ...

Sexual health and function among patients receiving systemic therapy for primary gynecologic cancers

ObjectiveSexual dysfunction has been reported after gynecologic cancer treatment but few studies have examined sexual function during treatment. Our objectives were to describe sexual function among women receiving systemic therapy for gynecologic cancers and to compare sexual function between women receiving upfront treatment versus treatment for cancer recurrence. MethodsWe conducted a prospective study of women 18yo and older receiving systemic therapy for gynecologic cancer in the upfront or recurrent setting. Patients receiving radiation were excluded. Participants completed a survey with questions from the Patient Reported Outcome Measurement Information System (PROMIS) SexFS and Female Sexual Function Index (FSFI). Clinical information was collected from chart review. Statistical analysis included t-test, Wilcoxon rank sum test, and Fisher's exact test. ResultsOf 145 patients approached, 100 (69%) enrolled and 97 (67%) completed the survey. Median age was 65yo. Most patients had ovarian cancer (58%), then endometrial cancer (34%) and cervical cancer (8%). Fifty-two (54%) were receiving recurrent treatment and 45 (46%) upfront treatment. Thirty-eight (76%) in the recurrent group and 34 (75%) in the upfront group hadn't been sexually active in the last month (p = 1.0); however, 61 (67%) participants reported a desire for future sexual activity. Of the 31 patients who completed all FSFI questions, the median FSFI score was 24.0 and 21 (68%) had sexual dysfunction. Vaginal dryness was more common among patients receiving recurrent treatment (p = 0.09) while a “health condition” was a more common reason for sexual inactivity in the upfront setting (p = 0.07). ConclusionMany patients receiving systemic therapy for gynecologic cancers are willing to discuss sexual function. Most patients reported sexual dysfunction and weren't currently sexually active. Understanding patients' sexual function concerns will allow providers to intervene.

Female sexual dysfunction in patients with urinary incontinence and lower urinary tract symptoms.

This study was conducted to determine the frequency of female sexual dysfunction in patients with urinary incontinence and lower urinary tract symptoms (UI/LUTS). Female patients between 18 and 60 years of age with lower urinary tract symptoms for more than three months were included and Female Sexual Function Index (FSFI) questionnaire was administered. Ninety-seven patients with mean age of 48±12.61 years were included in this cross sectional study. Median FSFI score of our patients was 46 (IQR34-58). Moderate to severe effect of urinary symptoms on sexual life was reported by 71 (73%) patients. When patients with sexual dysfunction (FSFI<27) were compared with those without sexual dysfunction (FSFI>27) there was no difference in age, parity, menopausal status or severity of LUTS between the two groups. We conclude that sexual dysfunction is common among female patients presenting with LUTS irrespective of age, menopausal status or severity of LUTS.

Sexual Dysfunction in Women during COVID-19 pandemic: A Hospital-Based, Prospective, Cross-sectional Comparative Study

Objective: International studies have shown that overall sexual activity and frequency of sexual intercourse decreased significantly during the COVID-19 pandemic. The aim of this study is to compare the female sexual dysfunction (FSD) rate in women during the COVID-19 pandemic in tertiary hospital in Turkey. Method: A total of 150 participants who were 50 pregnant women (group I), 50 healthcare women (group II) and 50 other women (group III), participated in study. A female sexual function index (FSFI) questionnaire was applied to the women along with the questions of age, education level, delivery methods, smoking, employment status and socioeconomic levels. The sexual dysfunction rate and female sexual function index scores between the groups were compared. Results: The median FSFI score was 23.50 in the present study population. Median scores were 22.1, 26.5, and 23.1 for groups I (pregnant), II (healthcare workers) and III (others), respectively. When the FSFI scores of the groups were compared, the FSFI score of group II was statistically significantly higher than the other groups (p: 0,001). By using the cutoff FSFI score of 26.55, 68.7 % (n:103) of women were diagnosed as having sexual dysfunction. The rates of sexual dysfunction as follows 84%, 52%, and 70% for groups I, II and III, respectively. When analyzed with FSFI domains one by one, it was seen that Group 2 had a statistically significantly higher FSFI score in the areas of Arousal, Lubrication, Orgasm, and Pain compared to the other groups. Conclusions: The prevalence of FSD in Turkey increased during COVID-19 pandemic. When comparing female sexual dysfunction prevalence in groups, the lowest sexual dysfunction prevalence was found in healthcare workers. Prevalence of sexual dysfunction was found to be associated with women's employment and educational status.

Bariatric surgery has positive effects on patients' and their partners' sexual function: A prospective study.

Obesity has been associated with severe conditions and sexual dysfunction. Bariatric surgery has effects positively patients' sexual function. To assess the effect of bariatric surgery on sexual functions of couples. The study included 57 obese patients and their sexually active partners. Male participations were assessed with the International Index of Erectile Function (IIEF) and Male Sexual Health Questionaries (MSHQ-4), and female participations were assessed with the Female Sexual Function Index (FSFI). There were 31 (54.4%) male patients and 26 (45.6%) female patients in the study. The median IIEF score of the male patients statistically increased postoperatively (p<0.001). The IIEF subgroup areas were found to have increased after surgery. The median FSFI score of the female patients statistically increased postoperatively (p<0.001). The median FSFI of male patients' partners significantly increased postoperatively (p<0.001). All FSFI domains were statistically significantly increased (p<0.001, all areas). The median IIEF value of the postoperative partners of the female patients also increased statistically significant (p<0.001). In addition, the increases in the IIEF's subdomains in terms of sexual desire (p<0.001), intercourse satisfaction (p<0.001), and general satisfaction (p<0.001) were statistically significant. The sexual functions of both males and females and also their' partners were improved after bariatric surgery. Patients with preoperative poor sexual function achieve significant benefits over patients without sexual dysfunction.

Sexual Dysfunction in Survivorship; the Impact of Menopause and Endocrine Therapy.

Sexual dysfunction is common for breast cancer survivors. Premenopausal women with breast cancer are increasingly offered ovarian suppression and aromatase inhibitor (AI) therapy. We evaluated the association of menopausal status and treatment modalities on sexual dysfunction. We conducted a cross-sectional anonymous Female Sexual Function Index (FSFI) survey of breast cancer survivors between 2000 and 2016. Analysis utilized Kruskal-Wallis test for FSFI scores, Chi square, or Fisher's exact test for categorical data, and regression analysis for associations. Of 585 respondents, 278 (47.5%) had complete FSFI scores. Of these, 24 (8.6%) were premenopausal and 80 (28.8%) were pre/perimenopausal at survey completion. Median FSFI scores for premenopausal (31.2, interquartile range [IQR] 26.8-33.6) and pre/perimenopausal (29.2, IQR 25.9-32.2) were similar, whereas postmenopausal women (25.9, IQR 21.0-30.3) were significantly lower (p = 0.0007 and p = 0.0002, respectively). Premenopausal women were less likely to meet criteria for sexual dysfunction (FSFI score ≤ 26.55) than postmenopausal women (21 versus 55%, p < 0.0001, univariate analysis [odds ratio (OR) 0.32, 95% confidence interval (CI) 0.18-0.56]). Adjusting for treatment modality did not impact the significance (OR 0.43, 95% [CI] 0.23-0.80) but revealed that AIs independently are associated with sexual dysfunction (OR 2.41, 95% CI 1.32-4.40). The interaction between menopausal status and AIs was not significant (p = 0.24). Our study demonstrates that menopausal status is associated with sexual dysfunction in breast cancer patients and sexual dysfunction in premenopausal women is not impacted by treatment modality outside of aromatase inhibitor therapy. As more premenopausal patients are treated with ovarian suppression, these data may guide clinicians in counseling patients regarding sexual dysfunction expectations.

High Prevalence of Sexual Dysfunction in Women with Rheumatic Diseases: A not Recognized Health Domain

To measure the sexual satisfaction and the prevalence of dysfunction in women with rheumatic diseases. A cross-sectional study was conducted, in which the patients were enrolled in two clinical settings; Public Health Insurance and Social Security Service. The presence of sexual dysfunction was assessed with the questionnaire ‘Female Sexual Function Index (FSFI)’. The FSFI was self-administered and consisted of 19 questions covering six domains; desire, subjective arousal, lubrication, orgasm and pain. The patients’ answers were based on the 4 weeks prior to completing the questionnaire. A total score of ≤ 26 indicated sexual dysfunction. 451 women participated, mean age of 49.27 years (SD 13.58). The most frequent diagnoses were: Rheumatoid Arthritis (234, 51.9%), Systemic Lupus Erythematous (58, 12.9%), Osteoarthritis (35, 7.8%) and Fibromyalgia (25, 5.5%). The median FSFI score was 12.3 (IQR 12.8) and sexual dysfunction was found in 94.9% of patients. Median and IQR scores for each domain were as follows: desire 5.4 (2.4), subjective arousal 1.2 (3.3), lubrication 2.1 (3.9), orgasm 0 (3.6), satisfaction 2.4 (1.2) and pain 0 (4.8). There was no difference found between the rheumatic diseases studied and the FSFI score or the percentage of patients with sexual dysfunction. There is a negative correlation (Spearman rho − 0.328, p = 0.01) between age and the final score, a positive correlation between age and (0.449, p = 0.01) desire, and a negative correlation with the remaining categories: subjective arousal (rho = − 0.351, p = 0.01), lubrication (rho = − 0.387, p = 0.01), orgasm (rho = − 0.346, p = 0.01), and pain (rho = − 0.411, p = 0.01). The sexual dysfunction frequency in rheumatic patients is high. It is necessary to investigate and act on this problem to increase the quality of life of our patients.

Body mass index (BMI), postoperative appearance satisfaction, and sexual function in breast cancer survivorship.

We sought to explore the correlation between BMI and postoperative sexual function, body image, and breast-specific sensuality before and after breast cancer surgery. A cross-sectional survey of patients at least 1year from surgery employed the Female Sexual Function Index (FSFI) and investigator-generated questions. Patients who underwent lumpectomy (L), mastectomy (M), and mastectomy with reconstruction (MR) were compared across three BMI groups: normal weight, overweight, and obese. Two hundred fifty-five patients underwent lumpectomy (L, n=174), mastectomy (M, n=22), or mastectomy with reconstruction (MR, n=59). Median age was 57 (range 30-93) and median BMI was 28 (range 19-45). Obese and overweight women reported more appearance dissatisfaction (18.1 and 13.0%) than normal weight women (4.1%) (p=0.01). Lower satisfaction was associated with increasing BMI within the MR group (p=0.05). The obese group's median FSFI score met criteria for sexual dysfunction (25.90, range 11.30-33.10). More overweight women reported their chest played an important role in intimacy before and after surgery, but a postoperative decline in the importance of this role was observed in all groups. Greater post-treatment BMI is inversely related to postoperative appearance satisfaction, particularly in those undergoing mastectomy with reconstruction. The role of the breast in intimacy is greatest in overweight women, but decreases postoperatively in all BMI groups. Postoperative appearance satisfaction and sexual function seems to be correlated to post-treatment BMI, which highlights the need to encourage perioperative weight management for improved survivorship outcomes.

Breast-Specific Sensuality and Sexual Function in Cancer Survivorship: Does Surgical Modality Matter?

More early-staged breast cancer patients are choosing mastectomy. No studies have addressed breast-specific sensuality (BSS), defined as the breast's role during intimacy. We explored BSS among women undergoing lumpectomy (L), mastectomy alone (M), or with reconstruction (MR) and analyzed the association of surgical modality with sexual function. Women undergoing breast cancer surgery between 2000 and 2013 were eligible for survey using investigator-generated questions and the Female Sexual Function Index (FSFI). Demographic and surgical data were collected by chart review. The Kruskal-Wallis test was used to analyze FSFI scores, and χ 2 or Fisher's exact tests were used for categorical data. Of 453 invited participants, 268 (59%) completed the survey. Of these, 69.4, 22.4, and 8.2% underwent L, MR, or M, respectively. The importance of the breast/chest wall during intimacy declined significantly regardless of surgical modality (L 83-74%, p=0.0006; M 95-47%, p=0.003; MR 93-77%, p=0.002). No difference in sexual function was found between L, MR, and M (median FSFI score 28.2, 27.5, 25.9, respectively; p=1.0). Comparing L versus MR, higher FSFI scores resulted with appearance satisfaction (29.0 vs. 22.6 p=0.002) and preserved BSS as pleasurable breast caress (28.8 vs. 26.5, p=0.04) and the breast as part of intimacy (28.8 vs. 24.8, p=0.1). Breast cancer surgery is associated with lowered BSS. However, BSS and appearance satisfaction scores are better for L and appear to correlate with improved sexual function postoperatively. These data may guide surgical counseling and contribute to survivorship outcomes.

Sexual dysfunction and its determinants among women infected with HIV.

To describe the prevalence of female sexual dysfunction (FSD) and its determinants among women with HIV infection enrolled for care and treatment in an ambulatory care setting. A questionnaire-based cross-sectional survey was conducted among women attending the HIV clinic of Jos University Teaching Hospital, Nigeria, between March 2013 and February 2014. The self-administered Female Sexual Function Index (FSFI) was used to assess FSD; a score of less than 26.55 indicated FSD. Pearson coefficient was used to assess interdomain correlation, and multiple linear regression was used to identify factors associated with FSD. Among 370 participants, 330 (89.2%, 95% confidence interval [CI] 85.6%-92.2%) had FSD. The overall median FSFI score was 19.2 (interquartile range [IQR] 6.4-23.9). The arousal domain had the lowest subscore (median 2.7, IQR 0.0-3.6). The highest interdomain correlations were between lubrication and orgasm (r=0.87), arousal and lubrication (r=0.84), and arousal and orgasm (r=0.81) domains. Satisfactory health (β=3.34, 95% CI 1.16-5.52) and history of alcohol use (β=2.38, 95% CI 0.28-4.47) were independently associated with FSD. FSD was prevalent among women with HIV infection. Care providers need to routinely address FSD as part of a comprehensive care package in the study setting.

Female Sexual Dysfunction among Chinese Primiparous Women

Objective: To compare sexual function between primiparous women who underwent cesarean section (CS) and those who delivered vaginally. Methods: This cross-sectional study was conducted from October 2011 to April 2012 in Beijing, China. The target population included women aged 18 - 45 years who had given birth only once at least 6 months prior. The questionnaire was self-administered including female sexual function measured using the Female Sexual Function Index (FSFI). Data were analyzed using R software with the significance level of 0.05. Results: A total of 1456 participants were included and 102 women (7.0%) declined. The median age of the participants was 35 years. The median time interval after childbirth was 6 years. The median FSFI score was 26.9 and prevalence of female sexual dysfunction (FSD) was 34.2%. Both the FSFI scores and the proportions of individuals with sexual disorders were similar between women undergoing CS and those having vaginal delivery for both individual domains and the full scale. Conclusion: There were insignificant differences in female sexual function scores and FSD prevalence between women undergoing CS versus vaginal delivery.

Effects of low sleep quality on sexual function, in women with fibromyalgia.

Sexual dysfunction is a common experience in women with fibromyalgia. However, the physiopathology of this association is unclear. We aimed to evaluate whether sleep disturbance has an influence on sexual function in women with fibromyalgia. Fifty-four sexually active premenopausal women with fibromyalgia were enrolled in the study. The following questionnaires were used: the Female Sexual Function Index (FSFI), the Pittsburgh Sleep Quality Index (PSQI), the Fibromyalgia Impact Questionnaire (FIQ) and the Beck Depression Inventory (BDI). Appropriate statistical analyses were used by using SPSS 18. The mean FSFI score was 25.344 ± 6.52 and showed no correlation with age, body mass index, BDI or duration of fibromyalgia. However, a positive correlation between sexual dysfunction and low sleep quality was found (r=0.43; P=0.001). In addition, the median FSFI score was 29.2 (27.2-32.4) in patients with higher sleep quality (PSQI⩽5), whereas it was 21.4 (18.9-25.3) in patients with lower sleep quality (PSQI>5) (P<0.001). There was a positive correlation between sexual dysfunction and symptoms of fibromyalgia as indicated by a higher FIQ score (r=0.37; P=0.006). Sexual dysfunction in female patients with fibromyalgia may be due to low sleep quality. Treatment of the sleep disorder may improve female sexual function.

Sexual well-being in patients with vulvar disease: results from a preliminary prospective matched case–control study

IntroductionOnly a few studies have focused on the description of sexual well-being in patients with vulvar disease (VD). The aim of this study was to test the hypothesis that VD patients have an overall impaired sexual well-being that varies depending on the type of VD. Study designAn observational, prospective, single center and 1:1 matched case–control study was conducted in Nantes University Hospital (France). All new patients attending the specific consultation for VD between June 2011 and January 2013 were included. A control group was randomly selected from women who had a scheduled consultation for gynecologic follow-up. A validated French version of the Female Sexual Function Index (FSFI) was used. This self-administered questionnaire was distributed to all case and control women. VD was classified into 4 groups: inflammatory, (pre)malignant, infectious, and other VD. Descriptive statistics and multivariate mixed analyses were performed. ResultsSeventy-two VD patients and seventy-two control women completed the FSFI questionnaire. The median FSFI score was 21.1 in the VD patients versus 28.1 in the control patients. In the multivariate analysis, the FSFI score was significantly decreased by an average of 4.5 points (p=0.003) in the VD patients. On the FSFI subscores, VD had significant impacts on items related to “arousal”, “pain”, “lubrication”, “satisfaction”, and “desire”. When comparing the VD groups, the total FSFI score seemed lower for (pre)malignant VD. ConclusionThis preliminary study showed that VD patients had an impaired sexual well-being.

Evaluating sexual function in women after radical cystectomy as treatment for bladder cancer

Objective. Sexual function remains a relatively unexplored field within urology, especially for female patients who have undergone radical cystectomy (RC). The aim of this study was to shed light on this area. Materials and methods. The Female Sexual Function Index (FSFI) questionnaire and other selective questions regarding sexual function were sent to 71 women who had undergone RC and were alive 1 year postsurgery. Forty-one completed questionnaires were returned and analysed using simple descriptive statistical analysis, owing to the small sample size. Results. The median age of the patients was 67 years (range 39–91 years). Seventy-eight per cent reported being sexually active before surgery and 37% post-surgery. The median FSFI score postsurgery was 4.8 (range 1.2–32). The highest FSFI score was seen in the category of satisfaction, which consists of questions regarding closeness with partner, sexual relationship and overall sex life. Lowest FSFI scores were seen for lubrication, orgasm and pain. Twenty-seven per cent of patients wanted more information on the impact RC would have on their sex lives and many asked for information for their partners. Conclusion. Despite being based on a limited number of patients, this study indicates a need for improvement within this field. Most patients scored below 26 on the FSFI questionnaire, the cut-off for sexual dysfunction. However, many reported being satisfied overall. Thus, the physician’s main goal is to identify patients in need of more information and guidance before and after surgery.

Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early-stage endometrial cancer.

9104 Background: We performed a cross-sectional analysis of survivors of stage I endometrial cancer (EC) to examine the relationship between receipt of adjuvant intra-vaginal radiation therapy (IVRT), health state (HS), and sexual functioning (SF). Methods: Survivors were administered anonymous questionnaires containing demographic and treatment-related items, the EQ5D to measure current HS, and the Female Sexual Function Index (FSFI) to measure current SF. All were disease-free and had undergone simple hysterectomy (SH) with or without adjuvant IVRT at least one year prior to questionnaire completion. None had received chemotherapy or hormonal therapy. The study was IRB-approved under a waiver of consent. The primary endpoint was a comparison of EQ5D-health states and FSFI scores between survivors who had received SH alone and those who had received SH and adjuvant IVRT. Fisher’s exact test was used to compare IVRT and no-IVRT groups and multivariate regression was applied to find associations between factors and the outcome measures. Results: 136 (66.3%) participants had undergone SH alone and 69 (33.7%) had undergone SH and adjuvant IVRT. The SH alone group was younger; otherwise, the two groups were balanced with respect to ethnicity, marital status, education level, medical co-morbidities (diabetes, hypertension, anxiety), type of SH (laparotomy vs minimally invasive surgery-MIS), and baseline sexual activity. In the IVRT and no-IVRT groups, the median EQ5D-health states were 88 (range 40-100) and 85 (range 10-100) respectively, and the median FSFI scores were 14.1 (range 1.2-35.4) and 16.5 (range 1.2-34.8) respectively. Controlling for age and type of SH, receipt of IVRT was associated with better HS (p=0.018) and not associated with poorer SF (p=0.1399). Receipt of laparotomy (vs MIS) was associated with poorer HS and worse SF (p=0.0156 and p=0.0115, respectively), and its detrimental effect on FSFI score was more pronounced in the IVRT compared to no-IVRT group (p=0.0486). Conclusions: Compared to SH alone, receipt of adjuvant IVRT was generally not associated with poorer SF or HS.

Prevalence and risk factors for sexual dysfunction in gynecologic tumors survivors.

e19622 Background: Oncologic treatments for gynecological tumors are known to cause deleterious effects on sexual health. Relatively little attention has been focused on studying sexual dysfunction in these women despite it negatively impact on their quality of life. Methods: Women with all types of gynecological tumors were asked to participate in the survey. All participating patients had finished treatment for at least 6 months and were free of disease. Sexual function was assessed by the validated spanish version of the Female Sexual Function Index (FSFI), a 19-item self-report measure of six separate domains consisting of desire disorder, arousal disorder, orgasmic disorder, sexual pain disorder, vaginal lubrication and global sexual and relationship satisfaction. Scores below 24 were considered as indicators of sexual dysfunction. Results: 50 women with ovarian (n=25), endometrial (n=10) and cervical cancer (n=15) answered the questionnaire. Mean age was 51.4 years (28-70). Thirt-three patients (74%) reported sexual dysfunction. Median FSFI score was 15.15 (4.3-23.45). Lower FSFI scores corresponded to desire and vaginal lubrication disorder. No associations were found between sexual dysfunction and tumor type, stage, time from the diagnosis, previous chemotherapy, hormonotherapy and menopause at the time of the diagnosis. Lower levels of education, depression, previous radiotherapy treatment, vaginal dryness and lack of stable partner were predictors of worse sexual functioning. Conclusions: Our survey confirms the extend of impaired sexual functioning among gynecologic tumors survivors. Although numbers are small, certain factors may predict for patients at higher risk to present with sexual dysfunction and help to anticipate problems and develop guided therapy. No significant financial relationships to disclose.